Ivax Launches Neurontin Generic “At Risk” As Pregabalin User Fee Date Nears
Executive Summary
Ivax' "at risk" launch of generic gabapentin comes less than two weeks before the anticipated FDA user fee date for Pfizer's Neurontin follow-on drug Lyrica